Literature DB >> 16398024

Colony stimulating factor augmentation in human placental conditioned medium.

D S Verma1, G Spitzer, M Beran, A R Zander, K B McCredie, K A Dicke.   

Abstract

Because of the variability of different placentas to condition culture medium for colony-stimulating factor (CSF), we have attempted to augment CSF elaboration using endotoxin and bacillus Calmette Guerin (BCG) during the incubation period. Of 14 batches of human placental conditioned media (HPCM) prepared from different placentas, six were found to be inactive (no colony formation at concentrations of 5% to 40% vol/vol), five were found to be a weak stimulator of colony formation (producing < 10 colonies/10(5) human marrow cells plated at a HPCM concentration of 30%) and three were found to be active (producing 30 or more colonies/10(5) cells plated at HPCM concentration of 30%). In six cases augmentation of CSF elaboration was attempted using endotoxin or BCG and in all a marked increase in CSF was achieved. The increased colony formation was found to be due to greater increase in neutrophil and macrophage colonies than eosinophil colonies. The method of augmenting CSF elaboration in HPCM could have important implications for producing large quantities of potent and standardized source of CSF for the use in clinical laboratories and for increasing the yield of colony-stimulating factor(s) for further purification.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 16398024

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay.

Authors:  J A Ajani; B Tomasovic; G Spitzer; J J Kavanagh; D Thielvoldt; F L Baker; D Gershenson
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

2.  Medroxyprogesterone acetate does not protect human bone marrow progenitor cells exposed to adriamycin in vitro.

Authors:  G E Umbach; G Spitzer; B Drewinko; G Gercovich; G Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate.

Authors:  G E Umbach; G Spitzer; J A Ajani; V Hug; H Thames; F B Rudolph; B Drewinko
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays.

Authors:  G E Umbach; V Hug; G Spitzer; B Tomasovic; H Thames; J A Ajani; B Drewinko
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

5.  Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.

Authors:  G E Umbach; V Hug; G Spitzer; H Thames; B Drewinko
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

6.  In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells.

Authors:  J A Ajani; G Spitzer; B Tomasovic; B Drewinko; V M Hug; K Dicke
Journal:  Br J Cancer       Date:  1986-10       Impact factor: 7.640

7.  Human myeloid leukaemic cell interactions in vitro with normal myeloid colonies.

Authors:  G Spitzer; D S Verma; M Beran; A R Zander; K A Dicke; K B McCredie; S Siegel; S Tindle
Journal:  Br J Cancer       Date:  1981-02       Impact factor: 7.640

8.  Infusion-rate independent cellular adriamycin concentrations and cytotoxicity to human bone marrow clonogenic cells (CFU-GM).

Authors:  R Raijmakers; P Speth; T de Witte; P Linssen; J Wessels; C Haanen
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.